Kinesiotaping in Trauma
Launched by ONZE LIEVE VROUWE GASTHUIS · Jul 27, 2023
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of kinesiotaping as a way to help reduce pain in patients with certain shoulder and chest injuries, such as rib fractures or dislocated joints. When people come to the emergency department with these injuries, they often experience severe pain, which is typically managed with pain medications and a sling. Kinesiotaping is a method where special tape is applied to the skin to support the injured area, and some earlier studies have suggested it may help lessen pain, but more research is needed to confirm its effectiveness.
To participate in this trial, you must be at least 18 years old and have had an acute injury (meaning it happened within the last 24 hours) to the shoulder or chest. The study is looking for people with specific types of injuries, such as a single rib fracture or a mild shoulder dislocation. Participants will not be accepted if they have more serious injuries or certain health conditions. If you join the trial, you may receive either kinesiotaping or standard care to help manage your pain. The goal is to see if kinesiotaping can make a meaningful difference in how people feel, so it’s an important step towards improving treatment options for these types of injuries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥18 years
- • Acute injury (occurred \<24 hours ago)
- * Single shoulder or chest wall injury, which includes one of the following injuries:
- • rib fracture
- • disruption of the AC-joint Tossy type 1 and 2
- • not or hardly dislocated fracture of the clavicle
- • Not or hardly dislocated fracture of the r proximal humeral fracture
- Exclusion Criteria:
- • • Patients younger than 18 years
- • Incapacitated persons
- • Refusal of participation
- • Intubation indication
- • Decrease of Consciousness
- • Hemodynamic instability
- • 3 or more rib fractures
- • Rib fracture rib 1-3
- • Indication for surgery
- • Hospitalization required
- • Presence of a haemo- or pneumothorax with chest drain indication
- • Already known with allergy for adhesive tape
- • Patients with very thin or loose skin on the applicable body part
- • Skin infection/irritation or open wound on the applicable body part
- • Patients who do not speak Dutch or English
About Onze Lieve Vrouwe Gasthuis
Onze Lieve Vrouwe Gasthuis (OLVG) is a leading academic medical center located in Amsterdam, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, OLVG integrates cutting-edge medical practices with rigorous scientific inquiry, aiming to enhance patient outcomes and contribute to the global body of medical knowledge. The institution emphasizes collaboration among multidisciplinary teams, ensuring that trials are conducted with the highest ethical standards and adherence to regulatory guidelines, ultimately striving to translate research findings into meaningful improvements in patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Patients applied
Trial Officials
Mireille Bakker, MSc
Principal Investigator
OLVG
Maro Sandel, MD, PhD
Study Chair
OLVG
Carel Goslings, MD, PhD
Study Chair
OLVG
Janneke Schuitenmaker, MSc
Study Chair
OLVG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported